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ABSTRACT
Leprosy remains a public health problem in Brazil, and the Mato Grosso do Sul State 
(MS) had the seventh highest rate of detection of new cases in the country in 2015 (26.59 
per 100,000 inhabitants) which was classified as very high. This work aimed to determine 
the epidemiological characteristics of leprosy in MS. Descriptive statistics were performed 
with data from the Information System on Diseases of Compulsory Declaration (SINAN) 
between 2001 and 2015, with all patients included in the system serving as the sample. 
Clinical forms of multibacillary (MB) leprosy predominated in MS during the study period, 
with a clear positive trend from 2009 to 2015 and a peak in the detection rate of new cases 
(NCDR) in 2014 corresponding to 40.39 per 100,000 population (p<0.001). The most affected 
groups were men (56.7%) aged 20–59 years (70.52%), an economically active population. 
We observed that Northern MS had the highest overall NCDR in the State. In cities bordering 
other countries, NCDRs were significantly lower than in those of other analyzed cities. There 
was no dependency ratio correlating NCDRs in cities with higher or lower indexes with 
basic care coverage (p=0.799) and human development index (p=0.887). In conclusion, the 
large number of patients with MB leprosy indicates that the diagnosis of leprosy is delayed 
in MS, perhaps due to difficulties related to diagnostic methods. This situation contributes 
to the continuing prevalence of leprosy in MS. 
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INTRODUCTION
Leprosy is a chronic infectious disease caused by Mycobacterium leprae, which 
predominantly affects the skin and peripheral nerves, giving rise to deformities 
such as muscle wasting and injuries in anaesthetized areas of the body1. Leprosy 
is a leading cause of preventable disabilities, leaving 3 million people disabled 
worldwide2. The bacillus has high infectivity and low pathogenicity, with a long 
incubation period ranging from 2 to 7 years. Transmission between humans is 
considered the main way to contract the disease, and people living in the same home 
as the bacillus carrier are the most susceptible2,3. Leprosy in children younger than 
15 years old and the persistently high rate of disabilities in new cases are a robust 
indicator that leprosy transmission is continuing unabated4,5.
For the purposes of diagnosis and definition of a therapeutic regimen with 
multidrug therapy (MTD), the World Health Organization (WHO) has established 
the classification of leprosy based on the number of skin lesions. Patients with up 
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to five lesions are grouped as having paucibacillary leprosy 
(BP) and those with more than five cutaneous lesions, 
are classified as having multibacillary leprosy (MB)6,7. 
Untreated patients with MB leprosy are likely the most 
important source of M. leprae transmission; it is estimated 
that people who have contact with these patients have a 
5-10 times greater risk of acquiring the disease than the 
general population8,9.
WHO’s goal of eliminating leprosy by 1991 was reached 
globally, but the disease remains a public health problem 
in some countries10. The disease remains endemic in the 
Americas, with Brazil reporting the highest number of 
cases among all countries in the region. This high level of 
endemicity in Brazil is especially concentrated in the North, 
Northeast, and Central-West (CW) regions, with a very high 
detection rate of new cases (NCDR) and prevalence rate11-13.
The CW region presented the second highest NCDR in 
the country in 2010, being classified as endemic with an 
unequal distribution14. In 2011, Mato Grosso do Sul State 
(MS) showed a reduction in the prevalence rate; however, 
despite this decrease, the State requires intensification of 
measures to eliminate the disease15. It is imperative to 
implement regional descriptive studies to better understand 
the distribution of leprosy at the local level, with a focus 
on aspects associated with the operational classification of 
the disease that may contribute to prevention, diagnosis 
and early treatment, increasing the effectiveness of control 
and avoiding disabilities and deformities caused by leprosy. 
Therefore, the aim of this observational study was to 
delineate the epidemiological profile and to determine the 
trend of leprosy in MS from 2001 to 2015, analyzed through 
the database of government notifications, correlating these 
data with social and health indicators.
METHODS
Study design
We conducted a retrospective cross-sectional ecological 
study of 11,516 patients with leprosy reported in MS 
between January 2001 and December 2015. Data were 
obtained from notifications to the Information System on 
Diseases of Compulsory Declaration (SINAN), Department 
of Informatics of the Brazilian Unified Health System 
(DATASUS), Instituto Brasileiro de Geografia e Estatistica 
(IBGE) and Department of Basic Care (DAB)15,16. 
Study area and population
The Mato Grosso do Sul State is located between 
the latitude -20°30’0 S and the longitude -55°0’0 W. It 
is organized in 79 cities with a population density of 
6.86 inhabitants/km2, an area of 357,145.534 km2 and 
a population of 2,449,024 inhabitants17. The human 
development index (HDI) of MS is 0.729, which is 
considered average18. The unified health system (SUS) 
in MS is organized in 765 Family Health Strategy (FHS, 
primary care) teams distributed throughout the state. It 
is estimated that 76.6 % of the population has access to 
primary care19.
Study variables
The variables of the study were: cases confirmed by 
year, city of diagnosis, operational classification, current 
therapeutic scheme, outcome, sex, age group, assessment 
of the degree of physical incapacity at diagnosis, HDI and 
FHS. 
Data collection 
Cases confirmed between January 2001 and December 
2015 were retrieved from the SINAN online database, 
SinanWeb16. The use of this website was abandoned due 
to security problems, so that information became available 
through the DATASUS website15. We could confirm the 
cities belonging to MS State, the HDI and the number of 
inhabitants using data from IBGE18; data on FHS in the 
cities analyzed were retrieved from the DAB website20. 
Inclusion and exclusion criteria
As notification in Brazil is mandatory, we included all 
patients reported in SINAN with diagnosis of leprosy. Cases 
defined in SINAN as “diagnostic errors” were excluded 
from the analysis.
Statistical analysis
In this study, descriptive statistics were performed 
to analyze the obtained data. To describe the detection 
rate of new cases (NCDR) and the prevalence of leprosy, 
95% confidence intervals were determined for binomial 
distributions21. For the prevalence rate, cases in a possible 
course of treatment were considered, including all the cases 
diagnosed in the year and two years prior to the year of 
evaluation, by 10,000 inhabitants from a certain geographic 
space. The NCDR of leprosy was calculated based on the 
number of cases detected in a year multiplied by 100,000 and 
divided by the total population in that year22. The chi-square 
test was used to verify if there was a significant difference 
in NCDRs between years, with 2001 as the base year, and 
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between the NCDRs of PB leprosy and MB leprosy in each 
year. The significance level was set at 5%23. A multiple 
linear regression was used to test the independence between 
response variables and control ones. A bilateral Mann–
Whitney U test of independent samples was used to test the 
hypothesis21. The software used in the analyses was R-project 
for statistical computing (version 3.2.4).
Ethical considerations
Considering that this manuscript used only a database 
with aggregated information and no possibility of individual 
identification, the resolution 510/16 from the National 




In this study, we found that most of the population 
diagnosed with leprosy was composed of males (56.7%; 
N=6,530). Of these, 61.84% (N=4,610) were affected 
by the multibacillary form (MB); most individuals with 
the paucibacillary form (PB) were females (52.85%; 
N=2,132). There was a predominance of patients between 
20 and 59 years old (70.52%; N= 8,101), with a higher 
proportion of MB leprosy among patients over 60 years old 
(25.45% MB vs. 16.71% PB). The majority of patients who 
completed treatment were considered cured according to 
SINAN’s criteria (85.91%; N= 7,338); patients with the PB 
form had a greater chance of cure than those with the MB 
form (p<0.001). This finding may be related to the shorter 
treatment time in PB patients, increasing the percentage of 
patients who completed treatment when compared to MB 
patients (Table 1). 
Leprosy in Mato Grosso do Sul, the Central-West 
Region, and throughout Brazil 
In the period from 2001 to 2015, 664,500 leprosy 
patients were notified nationwide (some from periods before 
the establishment of SINAN). Of these, 59.3% (N= 393,990) 
had MB leprosy, 40.36% (N= 268,237) had PB leprosy and 
0.34% (N= 2,273) had an unknown situation (not notified 
or improperly notified). In the entire CW Region, 112,193 
cases were confirmed, representing 16.89% of the cases in 
the country; cases in MS accounted for 10.14% of cases 
in the region. In the 15-year period, MS reported 11,374 
patients (144 cases prior to SINAN), with a predominance 
of MB leprosy (65.3%; N= 7.424).
Prevalence, NCDR and physical disabilities due to 
leprosy in Mato Grosso do Sul
Highest prevalence rates were observed during the 
period from 2001 to 2004, when compared to later years 
of the study. A sharply decrease was observed from 2004 
Table 1 - Epidemiological characterization of leprosy cases reported to the Information System on Diseases of Compulsory 




N % N %
Sex
Male 6530 56.70 1902 47.15 4610 61.84 ≤0,001
Female 4986 43.30 2132 52.85 2845 38.16
Age (years)
0 to 19 816 7.10 511 12.67 305 4.09 ≤0,001
20 to 59 8101 70.52 2849 70.62 5252 70.46
60 or older 2571 22.38 674 16.71 1897 25.45
Outcome
Cure 7338 85.91 3217 90.85 4110 82.43 ≤0,001
Transf. to the same city 77 0.90 16 0.45 61 1.22
Transf. to another city 236 2.76 41 1.16 195 3.91
Transf. to another state 94 1.10 17 0.48 77 1.54
Transf. to another country 19 0.22 5 0.14 14 0.28
Died 162 1.90 13 0.37 147 2.95
Abandoned 350 4.10 138 3.90 212 4.25
Unspecified Transf. 265 3.10 94 2.65 170 3.41
Abbreviations: Transf: transference; PB: paucibacillary; MB: multibacillary. *Association between the variables characterizing the 
sample and the type of leprosy (pauci and multi) were analyzed by the Chi-square test.
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to 2005 and from 2009 to 2010, with a reduction of 84.5% 
and 93% respectively. From 2005 to 2007, the leprosy 
prevalence increased by 76.87% and decreased by 15.75% 
from 2007 to 2008. Between 2010 and 2012, the prevalence 
remained on the average of 0.14 per 10,000 inhabitants, 
however, during the period of 2012 to 2015, there was 
a sharply increase of this rate, going from 0.12 to 2.28 
respectively, which represented an increase of 1,900 % in 
the period. This made the prevalence rate again similar to 
the average found between the years 2005 to 2009, which 
was 2.1 per 100,000 inhabitants (Table 2). 
Regarding the NCDR, 2014 presented the highest value 
in the analyzed period, with an increase of 56%. When 
we observed the new cases detected in 2014 compared 
to 2007 (the highest and the lowest rate in the studied 
period, respectively), there was an increase of 70%, which 
means almost two times more new cases detected in 2014 
in comparison to 2007 (Table 2). In the mildest form, PB 
leprosy, there was a considerable reduction of new cases 
from 2010 onward (p<0.001), with a decline of 68% during 
all the evaluated period (from 12.5 to 3.93). On the other 
hand, the NCDR from the MB form showed an increase of 
59% (from 14.26 to 22.66) from 2001 to 2015. There was 
also a significant increase in the proportion of NCDR from 
MB cases in relation to the year 2001, from 2010 onward 
(p=0.001) (Table 2). 
When confirmed cases were analyzed according to the 
current operational classification by the year of notification, 
we observed that the number of newly infected patients grew 
each year. However, in 2015 there was a significant decline 
compared to 2014 (p=0.044). PB cases showed a significant 
decline, while MB cases rose until 2014 (Figure 1).
In the period between 2001 to 2015, the average of 
NCDR in leprosy cases with grade 2 physical disabilities 
assessed at the time of diagnosis was 1.94 per 100,000 
Figure 1 - Cases confirmed by the operational classification 
of leprosy in the Mato Grosso do Sul State, Brazil, from 2001 
to 2015.
Table 2 - Prevalence, new case detection rate (NCDR) and degree 2 of leprosy disabilities o in the Mato Grosso do Sul State from 
2001 to 2015. 
Year Prevalence¹ NCDR² p-value³ PB NCDR² p-value³ MB NCDR² p-value³
NCDR with 
Grade 2 of 
disability
p-value3
2001 27 26.76 - 12.50 - 14.26 - 1.52 -
2002 22.13 28.87 0.212 14.46 0.094 14.41 0.973 1.45 0.9674
2003 22.11 32.82 <0.001 17.00 <0.001 15.82 0.218 2.12 0.7510
2004 9.49 31.56 0.003 16.36 0.001 15.20 0.399 1.59 0.9681
2005 1.47 26.94 0.821 14.36 0.082 12.58 0.142 1.41 0.9484
2006 1.62 26.63 0.976 12.90 0.667 13.73 0.742 1.39 0.9388
2007 2.60 24.98 0.136 10.78 0.061 14.20 0.782 2.32 0.6802
2008 2.19 26.75 0.808 12.05 0.839 14.70 0.577 1.76 0.8937
2009 2.60 24.78 0.620 9.74 0.114 15.04 0.039 1.4 0.9436
2010 0.16 26.66 0.840 8.15 <0.001 18.50 <0.001 2.74 0.5502
2011 0.15 29.30 0.086 8.21 <0.001 21.09 <0.001 1.94 0.8198
2012 0.12 34.25 <0.001 8.66 <0.001 25.59 <0.001 1.76 0.8937
2013 3.0 26.05 <0.001 5.85 <0.001 20.2 <0.001 2.51 0.6183
2014 3.91 40.39 <0.001 7.39 <0.001 33.00 <0.001 2.48 0.6278
2015 2.28 26.59 0.220 3.93 <0.001 22.66 <0.001 2.75 0.5474
¹Per 10,000 inhabitants. ²NCDR: New case detection rate per 100,000 inhabitants, PB (paucibacillary), MB (multibacillary) leprosy. 
³Chi-square test comparing years. 
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population. However, Table 2 shows that there was a 
steady trend for this rate with little non-significant variation 
between the analyzed years (p>0.05) and the highest 
detection rate in 2015, presenting a value of 2,75 per 
100,000 inhabitants, an increase of 80% in relation to the 
year 2001, classified as high and indicating a delayed early 
diagnosis of the disease.
Spatial analysis of leprosy in Mato Grosso do Sul
When analyzing the spatial distribution of leprosy, 
in addition to Pedro Gomes municipality with a rate of 
200.05 per 100,000 inhabitants, two other cities presented 
an NCDR greater than 100 (Paranaiba and Navirai) and 5 
had an NCDR above 50 (Coxim, Bodoquena, Bandeirantes, 
Agua Clara and Bonito), as shown in Table 3 and Figure 2A.
The cities of Pedro Gomes and Navirai had the highest 
NCDRs of PB leprosy, whereas one of the lowest rates in 
the State was found in Rio Negro and Campo Grande, with 
NCDRs of 5.07 and 6.00 per 100,000 inhabitants, respectively 
(Table 3). Using maps of the leprosy incidence in MS, we 
compared the spatial distribution according to operational 
classification (Figure 2B). We noted that there was a greater 
concentration of high MB leprosy incidence throughout the 
State compared to those of PB leprosy (Figure 2B). 
We evaluated the number of confirmed leprosy cases 
in MS cities directly bordering another country and those 
with an indirect border (cities within a 150-km distance 
from a border but with no contiguous border areas) 
between 2001 and 2015, as well as the respective NCDRs. 
We found no significant differences among border cities 
(bordering Bolivia, Paraguay, and those with an indirect 
border) with respect to general NCDR of leprosy among 
non-border cities. However, in cities bordering Bolivia, 
PB leprosy NCDRs (13.58 per 100,000 inhabitants) were 
significantly higher than in cities with other borders (9.45 
per 100,000 inhabitants); the NCDR for MB leprosy 
was lower (15.17 and 18.77 per 100,000 inhabitants, 
respectively). Cities with indirect borders had the lowest 
PB leprosy NCDRs (8.85 per 100,000 inhabitants) 
compared to other cities. When comparing border cities 
in MS with cities having the highest leprosy NCDRs in 
the state between 2001 and 2015, we observed that the 
NCDRs in border cities (28.55 per 100,000 inhabitants) 
were significantly lower than those of the other cities 
analyzed (88.82 per 100,000 inhabitants) (Table 3).
The comparison of cities with the highest leprosy 
NCDRs with those having the lowest incidences, and 
considering the HDI and FHS coverage, we observed that 
there was no significant dependency relationship of the 
variable NCDR response with the control variables FHS 
(p=0.799) and HDI (p=0.887). Nevertheless, Navirai, one 
of the cities with a NCDR greater than 100, had one of the 
lowest FHS coverage in that period.
Table 3 - Cities with the highest new case detection rate of leprosy, family health strategy (FHS) coverage and human development 
index (HDI) in Mato Grosso do Sul State, between 2001 and 2015.
City 
New case detection rate1 FHS 
Coverage HDI Total PB MB
Pedro Gomes 200.05 36.19 163.86 77.49 0.67
Paranaiba 137.11 25.43 111.68 83.65 0.72
Navirai 118.22 59.84 58.25 46.58 0.70
Coxim 95.69 12.44 82.65 72.01 0.70
Bodoquena 86.67 26.87 59.80 70.01 0.67
Bandeirantes 75.06 9.26 65.80 87.74 0.68
Agua Clara 52.67 17.24 35.43 76.81 0.67
Bonito 52.52 16.64 35.88 53.64 0.67
Rio Negro 46.69 5.07 41.61 95.79 0.71
Alcinopolis 43.13 6.16 36.97 83.79 0.71
Novo Horizonte do Sul 40.9 8.67 32.23 84.38 0.65
Rio Verde de Mato Grosso 37.43 10.62 26.81 98.82 0.67
Campo Grande2 15.68 6.00 9.62 25.3 0.78
Dourados3 20.3 10.08 10.11 56.31 0.75
1Per 100.000 inhabitants. 2Capital of Mato Grosso do Sul State. 3Second largest city in the state. Abbreviations: PB: paucibacillary 
leprosy; MB: multibacillary leprosy; FHS: family health strategy coverage; HDI: human development index.
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DISCUSSION
Brazil is the only Latin American country that has not 
achieved the goals proposed by the WHO for elimination 
of leprosy, although several control programs were 
created, and data presented by the Brazilian Ministry of 
Health have shown that the incidence in Brazil is slowly 
decreasing25,26. As far as we know, there are no temporal 
studies of epidemiological indicators covering long 
periods indicating trends for leprosy in Mato Grosso 
do Sul State. According to our results, the number of 
leprosy cases reported in MS between 2001 and 2015 
was consistent with the national representativeness of the 
state’s population (1.71% of cases in Brazil/ 1.28% of the 
national population)18,27.
Young adults were the most affected by leprosy in this 
study, suggesting a negative impact on the economy as the 
disease can cause disabilities and symptoms that prevent 
people from working28. In 2015, Silva et al.29, stated that 
the high number of patients with MB leprosy is alarming 
as it affects an economically active age group with greater 
likelihood of disease transmission29. According to a 1988 
WHO report and recent study by Ramos et al.30, although 
leprosy affects both sexes, men are affected more often than 
women with a ratio of 2:130. These data were confirmed in 
our study population in which significantly higher rates of 
the MB form were found in men between ages 20 and 59 
years (Table 1). 
The prevalence rate of leprosy in MS decreased from 
2001 to 2015, with emphasis in the period from 2004-2005, 
with a decrease of more than 80% (Table 2). In Brazil, in 
the same study period, there was a decrease of 20,000 new 
cases observed between 2003 and 2013 (40% reduction), 
coinciding with a period of significant decentralization 
of leprosy control activities in the country. From 2000 to 
2011, a 284% expansion in the number of health centers 
that registered patients under treatment (from 3,327 to 
9,445)31 was reported. Although MS followed the trend 
of the country, with a reduction of prevalence, in 2015, 
the last year of evaluation in this study, MS had a medium 
prevalence of 2.28 cases per 100,000 inhabitants, the 5th 
highest rate in the country, and a very high NCDR, 26.59 
cases per 100,000, inhabitants, representing the country’s 
seventh highest NCDR27.
Figure 2 - Spatial distribution of the incidence rate of leprosy in Mato Grosso do Sul State, Brazil, between 2001 and 2015. A) General 
incidence of leprosy. B) Paucibacillary and multibacillary leprosy incidence. PB: paucibacillary leprosy; MB: multibacillary leprosy.
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The very high leprosy NCDR in MS, as well as in 
other States, indicates the continuing transmission of the 
disease in Brazil. Clinical MB leprosy predominates in 
MS, with a clear positive trend from 2009 to 2015, while 
PB cases are decreasing. The increase of MB leprosy is 
showing that prevention of transmission has not been 
achieved despite implementation of multidrug therapy 
(MDT) programs and the creation of several control 
programs32. The number of disabilities at diagnosis has 
also been highlighted in the study. During the evaluated 
years, an increase in the new diagnosed cases with 
degree 2 of incapacities was observed, reflecting a delay 
in diagnosis and treatment, what is consistent with the 
ongoing transmission of infection33. The reduction of 
new PB form cases and the increment of new MB cases, 
together with the permanence of patients diagnosed with 
grade 2 of incapacities, may also show that more people 
are been diagnosed at an advanced stage, suggesting 
difficulties related to diagnostic methods, lack of access 
to more complex or precise methods and deficient basic 
care networks. Consequently, numerous cases remain 
undiagnosed and untreated, and these individuals will act 
as continuing reservoirs of infection and have a profound 
impact on the maintenance of the chain of transmission34.
It is worth mentioning that the Mato Grosso do Sul State 
has land borders (1,578 km) with two countries, Paraguay 
and Bolivia, and five other Brazilian states (Mato Grosso, 
Goias, Minas Gerais, Sao Paulo, and Parana). There is 
constant migration between countries and states from MS. 
For this reason, patients are diagnosed and treated for 
leprosy in MS regardless of their nationality, place of birth 
or legal status, and they are included in the state statistics. 
This situation could influence local NCDRs, which may 
be considered a limitation of the study, when the place of 
diagnosis is considered instead of the place of residence. 
However, we found no significant differences among border 
areas with Bolivia, Paraguay, as well as among indirect 
border areas in relation to the general NCDR, when among 
non-border cities were analyzed. In our study, only 11.6% of 
leprosy cases in MS occurred in cities bordering Paraguay. 
It is important to note that Paraguay has reached the WHO 
target for leprosy elimination, confirming that bordering 
this country is not a risk factor for leprosy35.
In relation to the distribution of leprosy by city, cities 
in Northern MS have quite high NCDRs compared to other 
parts of the state. The cities diverge reasonably, showing a 
heterogeneous distribution; however, ratio determination 
was difficult as it was not possible to confirm endemicity or 
the use of different detection strategies. Spatial analysis of 
leprosy is of paramount importance to verify the endemic 
areas scattered throughout the state12. However, according 
to Ramos et al.30, the spatial distribution of leprosy should 
be carefully analyzed owing to possible errors in detection, 
underreporting, and/or late diagnosis that may result in 
erroneous designation of low NCDR areas36. 
It is known that leprosy is directly associated with 
precarious health conditions and low socioeconomic 
status34. The knowledge about risk areas for leprosy reveals 
that the distribution is intimately linked to a number of 
factors that coincide for the maintenance of high rates 
of transmission and NCDR, including environmental, 
individual, socioeconomic and health service organization 
factors30. The results of this study showed that there were 
no significant differences in HDI and access to primary 
health care (HFS) between cities with higher and lower 
NCDR. However, three cities with more than 100 cases 
per 100,000 inhabitants were detected in the evaluated 
period: Pedro Gomes, Paranaiba and Navirai. All three 
cities are located in different parts of the state, bordering 
other states, on the North, South and East, been classified 
as hyperendemic regions. Not surprisingly, one of these 
cities, Navirai, has one of the lowest HFS coverage in that 
period. Although no differences were detected in the linear 
regression, these data may indicate that low coverage by 
family health strategies may have contributed to the high 
incidence of leprosy in this city.
Considering the findings of this study, it was possible 
to have a panoramic view of leprosy in MS State and 
identify possible risk areas. Despite the reduction in the 
leprosy prevalence rate, the NCDR with grade 2 disabilities 
and the multibacillary form NCDR had a considerably 
increase during the study period, highlighting the three 
municipalities, from different regions of the State, classified 
as hyperendemic for the disease. These findings suggest 
delays in case diagnosis and shortcomings in preventing 
disabilities, suggesting possible operational difficulties 
in controlling the disease. It is important to keep in mind 
that we used secondary data produced in different settings 
nationwide, thus leprosy classification methodology 
may vary according to the center diagnostic capacity. In 
addition, according to previous work that dealt with the 
national leprosy database, SINAN, there is a tendency 
to underestimate the real number of cases13,25. Although 
this may be considered a limitation, it is evident that a 
continuous active surveillance in this area is necessary, 
including strategies for strengthening the local leprosy 
control program and rebuilding professional expertise 
to achieve a successful reduction of the current leprosy 
detection rate in this region. This will prevent grade 2 
disability cases, especially in hyperendemic municipalities, 
finally reducing the disease burden and preventing 
disabilities. Considering the early diagnosis and the 
Zanella et al.
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empowerment of this population, awareness about leprosy 
needs to be increased and people should be encouraged to 
work in partnership with the health services to deal with 
the problem. Furthermore, social institutions within these 
areas, such as churches, kindergartens and schools should 
be encouraged to work jointly with health services, as they 
are located in risk areas.
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